Neurology

The Frontotemporal dementia market is expected to increase with a CAGR of 21.41% for 7MM during the study period. However, pharma companies such as TauRx Therapeutics, Axon Neuroscience SE, Prevail Therapeutics, Avid Radiopharmaceuticals, and Alector are actively working to buildup the Frontotemporal dementia pipeline. One of the most diverse groups of neurodegenerative conditions, Frontotemporal dementia (FTD), is the second most common form of dementia in a population of age under 65 years after Alzheimer’s. FTD is a result of progressive degeneration of frontal and temporal lobes of the brain that affects behaviour, problem-solving and decision-making capabilit...